Developer docs
API playgroundTry for free, no card

Search company profiles

ImmuVia

Full company profile

uuid00q6p75

Namestring
ImmuVia
Legal namestring
ImmuVia, Inc.
Websiteurl
immuvia.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ImmuVia is a privately held, pre-revenue biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts, that develops bispecific antibody therapeutics designed to induce tumor cell apoptosis without cytotoxic payloads. The company's foundational technology is the Cancerlysin™ platform, which engineers bispecific antibodies that bind a tumor-selective antigen (such as MUC16) on the cancer cell surface and use it as a scaffold to super-cluster DR5 death receptors, triggering the extrinsic apoptosis pathway. This mechanism is payload-free, immune-sparing, and does not require internalization — positioning ImmuVia's candidates as biologically orthogonal to antibody-drug conjugates (ADCs) and active in tumors with low-to-moderate antigen expression where ADCs are typically ineffective. The lead asset, IMV-M™, is a MUC16×DR5 bispecific antibody targeting non-small cell lung, ovarian, and pancreatic cancers and is currently in IND-enabling studies with first-in-human dosing projected within 12 months, with Phase 1 planned under Dr. Daniel Von Hoff at leading U.S. cancer centers. Two additional programs extend the platform: IMV-C (colorectal and gastric cancers, wholly owned, preclinical) and IMV-5 (acute myeloid leukemia, advancing on a partnering track).

ImmuVia's commercial strategy is a hybrid of clinical advancement and platform partnering. The company plans to run its own Phase 1 for IMV-M™, then advance wholly-owned programs through clinical development toward commercialization, while simultaneously seeking strategic partners to extend the Cancerlysin™ platform to new tumor-selective antigens and to develop indication-specific or regional collaborations. Revenue, when it materializes, is expected to come from licensing royalties, milestone payments, and partnership economics rather than direct product sales in the near term. The company is led by co-founders Iosif M. Gershteyn (CEO) and Victor S. Goldmacher (CSO), with a scientific team whose members are inventors of three FDA-approved antibody therapeutics (Kadcyla®, Elahere™, Sarclisa®) and who collectively hold 128+ issued US patents and 100+ publications.

The company has built scientific credibility through three peer-reviewed publications (Antibody Therapeutics 2024 and 2026; Nature Scientific Reports 2025), independent efficacy replication at TGen/City of Hope, and clean NHP safety at 4× therapeutic dose with zero hepatotoxicity. It holds an international PCT patent application for IMV-M™ and was selected for the Texas Medical Center 2025 Accelerator for Cancer Therapeutics. No funding rounds are disclosed in the available sources, which is a notable data point for a private biotech at IND-enabling stage.

Short descriptiontext

ImmuVia is a privately held, pre-revenue Cambridge, MA biotech developing payload-free bispecific antibody therapeutics built on its Cancerlysin™ DR5 super-clustering platform, targeting MUC16-positive solid tumors (IMV-M™) and hematologic malignancies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody therapeutics, targeted cancer therapy, oncology biologics pipeline, apoptosis therapeutics, antibody drug development
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bispecific Antibody Therapeutics / Oncology Biologics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline development and partnering
TypeLicensing Royalties
Description

Pre-revenue biotech company developing a pipeline of bispecific antibody therapeutics. Revenue strategy includes partnering on new targets, regional collaborations, and advancement of wholly-owned programs through clinical development to commercialization.

immuvia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Cancerlysin™
Description

Platform technology that applies apoptosis engine to new tumor-selective antigens; turns any clinically validated tumor antigen into a scaffold for tumor-restricted DR5 super-clustering

immuvia.com
Core offering1 text field

ImmuVia develops bispecific antibody therapeutics using its proprietary Cancerlysin™ platform, which super-clusters DR5 death receptors on tumor cells to trigger apoptosis without payloads or immune activation. The lead program IMV-M™ is a MUC16×DR5 bispecific antibody for NSCLC, ovarian, and pancreatic cancers, currently at IND-enabling stage with first-in-human dosing planned within 12 months. Additional programs include IMV-C (colorectal/gastric) and IMV-5 (acute myeloid leukemia, on a partnering track).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Clean NHP safety at 4× therapeutic dose with zero hepatotoxicity
+3 more records
Product overview1 text field

ImmuVia is a biopharmaceutical company developing a portfolio of Cancerlysin™ bispecific antibody therapeutics built on a proprietary apoptosis-inducing platform. The lead product IMV-M™ (MUC16×DR5 bispecific) is at IND-enabling stage for NSCLC, ovarian, and pancreatic cancers. Additional programs include IMV-C for colorectal/gastric cancer and IMV-5 for acute myeloid leukemia (the latter advancing on a partnering track). The Cancerlysin™ platform serves as the foundational technology enabling expansion to new tumor-selective antigen targets.

Product and service1 record
1IMV-M™
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Quantori's Q-Scientist platform selected to accelerate IMV-M™ development, providing computational and data science capabilities to support the IND-enabling and clinical development process.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Independent foundation-funded study replicated IMV-M™'s anti-tumor efficacy at TGen, part of City of Hope. Dr. Daniel Von Hoff's laboratory conducted the replication study, validating the company's preclinical data independently.

3New tumor target partners (seeking)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

ImmuVia is seeking partners to extend the Cancerlysin™ platform to new tumor-selective antigens. Partners can bring clinically validated antigens while ImmuVia builds the Cancerlysin™ therapeutic.

immuvia.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage developer of next-generation ADCs in oncology with multiple wholly-owned programs targeting solid tumors. Comparable to ImmuVia as a focused antibody-therapeutics company in oncology with platform-based pipeline expansion, though using payload-based ADC technology versus ImmuVia's payload-free bispecific approach.

TypeDirect peer
Description

Developer of Elahere (MUC16-targeting ADC) and Kadcyla — the same two FDA-approved antibody therapeutics the ImmuVia CSO and SAB helped invent. Directly comparable on the MUC16 ovarian-cancer target and on the antibody-therapeutics development playbook, though ImmunoGen's modality is payload-bearing ADCs versus ImmuVia's payload-free bispecific.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and ADCs in oncology, including prior DR5-targeting programs (e.g., enoblituzumab). Directly comparable as a bispecific/antibody-focused oncology company with DR5-targeting experience, addressing similar solid-tumor indications as ImmuVia.

TypeEmerging player
Description

Clinical-stage oncology biotech with a portfolio of bispecific antibodies including DR5-targeting candidates (e.g., CT900). Highly comparable to ImmuVia in modality (bispecific antibodies targeting DR5 in solid tumors) and stage, and serves as a useful benchmark for clinical translation of the DR5 bispecific thesis.

TypeBroad incumbent
Description

Large biotech with multiple approved bispecific antibodies (e.g., Hemlibra via partnership, Epkinly) powered by the DuoBody bispecific platform. Comparable to ImmuVia as a leading bispecific antibody platform company in oncology and hematology, though at much greater scale and with an established commercial portfolio.

TypeBroad incumbent
Description

Clinical-stage biotech developing engineered bispecific antibodies (XmAb platform) in oncology and autoimmune disease. Comparable to ImmuVia as a bispecific antibody platform company pursuing multiple oncology programs, though Xencor's broader XmAb platform addresses additional immune-mediated mechanisms.

7Elahere / AbbVie (ImmunoGen, acquired)
TypeBroad incumbent
Description

AbbVie acquired ImmunoGen and now commercializes Elahere (mirvetuximab soravtansine), the MUC16-targeting ADC. Comparable to ImmuVia as the established competitor in the same MUC16-positive ovarian cancer indication, against which IMV-M will be benchmarked on safety, efficacy, and combination potential.

TypeDirect peer
Description

Clinical-stage oncology company developing next-generation ADCs, including a MUC16 ADC program, with antibody payload and linker platforms. Directly comparable to ImmuVia as a MUC16-targeted solid-tumor developer with an antibody-based therapeutic platform, though using a different killing mechanism (payload vs. DR5 super-clustering).

TypeBroad incumbent
Description

Clinical-stage biotech with bispecific antibody platforms (Azymetric, zanidatamab) targeting oncology indications including HER2-driven tumors. Comparable to ImmuVia as a bispecific antibody platform developer in oncology, though at a more advanced clinical and commercial stage and focused on different tumor antigens.

TypeEmerging player
Description

Bispecific T-cell engager platform (TriTAC) oncology company (acquired by Merck). Comparable to ImmuVia as a clinical-stage bispecific antibody developer focused on solid tumors, addressing similar mechanism-of-action challenges around selectivity and tumor-restricted activity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmuVia

Bispecific Antibody Therapeutics / Oncology Biologicsimmuvia.com

ImmuVia is a privately held, pre-revenue Cambridge, MA biotech developing payload-free bispecific antibody therapeutics built on its Cancerlysin™ DR5 super-clustering platform, targeting MUC16-positive solid tumors (IMV-M™) and hematologic malignancies.

What ImmuVia does

ImmuVia is a privately held, pre-revenue biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts, that develops bispecific antibody therapeutics designed to induce tumor cell apoptosis without cytotoxic payloads. The company's foundational technology is the Cancerlysin™ platform, which engineers bispecific antibodies that bind a tumor-selective antigen (such as MUC16) on the cancer cell surface and use it as a scaffold to super-cluster DR5 death receptors, triggering the extrinsic apoptosis pathway. This mechanism is payload-free, immune-sparing, and does not require internalization — positioning ImmuVia's candidates as biologically orthogonal to antibody-drug conjugates (ADCs) and active in tumors with low-to-moderate antigen expression where ADCs are typically ineffective. The lead asset, IMV-M™, is a MUC16×DR5 bispecific antibody targeting non-small cell lung, ovarian, and pancreatic cancers and is currently in IND-enabling studies with first-in-human dosing projected within 12 months, with Phase 1 planned under Dr. Daniel Von Hoff at leading U.S. cancer centers. Two additional programs extend the platform: IMV-C (colorectal and gastric cancers, wholly owned, preclinical) and IMV-5 (acute myeloid leukemia, advancing on a partnering track).

ImmuVia's commercial strategy is a hybrid of clinical advancement and platform partnering. The company plans to run its own Phase 1 for IMV-M™, then advance wholly-owned programs through clinical development toward commercialization, while simultaneously seeking strategic partners to extend the Cancerlysin™ platform to new tumor-selective antigens and to develop indication-specific or regional collaborations. Revenue, when it materializes, is expected to come from licensing royalties, milestone payments, and partnership economics rather than direct product sales in the near term. The company is led by co-founders Iosif M. Gershteyn (CEO) and Victor S. Goldmacher (CSO), with a scientific team whose members are inventors of three FDA-approved antibody therapeutics (Kadcyla®, Elahere™, Sarclisa®) and who collectively hold 128+ issued US patents and 100+ publications.

The company has built scientific credibility through three peer-reviewed publications (Antibody Therapeutics 2024 and 2026; Nature Scientific Reports 2025), independent efficacy replication at TGen/City of Hope, and clean NHP safety at 4× therapeutic dose with zero hepatotoxicity. It holds an international PCT patent application for IMV-M™ and was selected for the Texas Medical Center 2025 Accelerator for Cancer Therapeutics. No funding rounds are disclosed in the available sources, which is a notable data point for a private biotech at IND-enabling stage.

ImmuVia firmographics

Firmographics
Name
ImmuVia
Legal name
ImmuVia, Inc.
Website
https://immuvia.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
ImmuVia is a privately held, pre-revenue Cambridge, MA biotech developing payload-free bispecific antibody therapeutics built on its Cancerlysin™ DR5 super-clustering platform, targeting MUC16-positive solid tumors (IMV-M™) and hematologic malignancies.
Ownership category
akta.pro rank

ImmuVia industry classification

Industry
Product category
Bispecific Antibody Therapeutics / Oncology Biologics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Bispecific antibody therapeutics
  • Targeted cancer therapy
  • Oncology biologics pipeline
  • Apoptosis therapeutics
  • Antibody drug development

Where ImmuVia is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ImmuVia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pipeline development and partnering: Pre-revenue biotech company developing a pipeline of bispecific antibody therapeutics. Revenue strategy includes partnering on new targets, regional collaborations, and advancement of wholly-owned programs through clinical development to commercialization.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

ImmuVia product offering

Product offering

Core offering

ImmuVia develops bispecific antibody therapeutics using its proprietary Cancerlysin™ platform, which super-clusters DR5 death receptors on tumor cells to trigger apoptosis without payloads or immune activation. The lead program IMV-M™ is a MUC16×DR5 bispecific antibody for NSCLC, ovarian, and pancreatic cancers, currently at IND-enabling stage with first-in-human dosing planned within 12 months. Additional programs include IMV-C (colorectal/gastric) and IMV-5 (acute myeloid leukemia, on a partnering track).

Product overview

ImmuVia is a biopharmaceutical company developing a portfolio of Cancerlysin™ bispecific antibody therapeutics built on a proprietary apoptosis-inducing platform. The lead product IMV-M™ (MUC16×DR5 bispecific) is at IND-enabling stage for NSCLC, ovarian, and pancreatic cancers. Additional programs include IMV-C for colorectal/gastric cancer and IMV-5 for acute myeloid leukemia (the latter advancing on a partnering track). The Cancerlysin™ platform serves as the foundational technology enabling expansion to new tumor-selective antigen targets.

Differentiator

Problem solved

Functional benefit

Brands

  • Cancerlysin™: Platform technology that applies apoptosis engine to new tumor-selective antigens; turns any clinically validated tumor antigen into a scaffold for tumor-restricted DR5 super-clustering

Products and services

  • IMV-M™

Quantifiable outcome

  • Clean NHP safety at 4× therapeutic dose with zero hepatotoxicity
  • +3 more outcomes

Companies that use ImmuVia

Customer profile

Segments2 records

Ideal customer profiles2 records

ImmuVia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ImmuVia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered supporting, core and minor.

  • QuantorisupportingTechnology or Integration · 1 April 2026Quantori's Q-Scientist platform selected to accelerate IMV-M™ development, providing computational and data science capabilities to support the IND-enabling and clinical development process.
  • TGen (City of Hope)coreStrategic or Co-development Partner · 1 October 2025Independent foundation-funded study replicated IMV-M™'s anti-tumor efficacy at TGen, part of City of Hope. Dr. Daniel Von Hoff's laboratory conducted the replication study, validating the company's preclinical data independently.
  • New tumor target partners (seeking)minorStrategic or Co-development PartnerImmuVia is seeking partners to extend the Cancerlysin™ platform to new tumor-selective antigens. Partners can bring clinically validated antigens while ImmuVia builds the Cancerlysin™ therapeutic.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

ImmuVia competitors and assessment

Company assessment

Emerging players

  • ProfoundBio: Clinical-stage developer of next-generation ADCs in oncology with multiple wholly-owned programs targeting solid tumors. Comparable to ImmuVia as a focused antibody-therapeutics company in oncology with platform-based pipeline expansion, though using payload-based ADC technology versus ImmuVia's payload-free bispecific approach.
  • Compass Therapeutics: Clinical-stage oncology biotech with a portfolio of bispecific antibodies including DR5-targeting candidates (e.g., CT900). Highly comparable to ImmuVia in modality (bispecific antibodies targeting DR5 in solid tumors) and stage, and serves as a useful benchmark for clinical translation of the DR5 bispecific thesis.
  • Harpoon Therapeutics: Bispecific T-cell engager platform (TriTAC) oncology company (acquired by Merck). Comparable to ImmuVia as a clinical-stage bispecific antibody developer focused on solid tumors, addressing similar mechanism-of-action challenges around selectivity and tumor-restricted activity.

Direct peers

  • ImmunoGen: Developer of Elahere (MUC16-targeting ADC) and Kadcyla — the same two FDA-approved antibody therapeutics the ImmuVia CSO and SAB helped invent. Directly comparable on the MUC16 ovarian-cancer target and on the antibody-therapeutics development playbook, though ImmunoGen's modality is payload-bearing ADCs versus ImmuVia's payload-free bispecific.
  • MacroGenics: Clinical-stage biotech developing bispecific antibodies and ADCs in oncology, including prior DR5-targeting programs (e.g., enoblituzumab). Directly comparable as a bispecific/antibody-focused oncology company with DR5-targeting experience, addressing similar solid-tumor indications as ImmuVia.
  • Mersana Therapeutics: Clinical-stage oncology company developing next-generation ADCs, including a MUC16 ADC program, with antibody payload and linker platforms. Directly comparable to ImmuVia as a MUC16-targeted solid-tumor developer with an antibody-based therapeutic platform, though using a different killing mechanism (payload vs. DR5 super-clustering).

Broad incumbents

  • Genmab: Large biotech with multiple approved bispecific antibodies (e.g., Hemlibra via partnership, Epkinly) powered by the DuoBody bispecific platform. Comparable to ImmuVia as a leading bispecific antibody platform company in oncology and hematology, though at much greater scale and with an established commercial portfolio.
  • Xencor: Clinical-stage biotech developing engineered bispecific antibodies (XmAb platform) in oncology and autoimmune disease. Comparable to ImmuVia as a bispecific antibody platform company pursuing multiple oncology programs, though Xencor's broader XmAb platform addresses additional immune-mediated mechanisms.
  • Elahere / AbbVie (ImmunoGen, acquired): AbbVie acquired ImmunoGen and now commercializes Elahere (mirvetuximab soravtansine), the MUC16-targeting ADC. Comparable to ImmuVia as the established competitor in the same MUC16-positive ovarian cancer indication, against which IMV-M will be benchmarked on safety, efficacy, and combination potential.
  • Zymeworks: Clinical-stage biotech with bispecific antibody platforms (Azymetric, zanidatamab) targeting oncology indications including HER2-driven tumors. Comparable to ImmuVia as a bispecific antibody platform developer in oncology, though at a more advanced clinical and commercial stage and focused on different tumor antigens.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

ImmuVia social profiles

Digital presence

ImmuVia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmuVia leadership team

Management profile

Number of profiles

Profiles11 records

ImmuVia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmuVia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmuVia

What does ImmuVia do?

ImmuVia develops bispecific antibody therapeutics using its proprietary Cancerlysin™ platform, which super-clusters DR5 death receptors on tumor cells to trigger apoptosis without payloads or immune activation. The lead program IMV-M™ is a MUC16×DR5 bispecific antibody for NSCLC, ovarian, and pancreatic cancers, currently at IND-enabling stage with first-in-human dosing planned within 12 months. Additional programs include IMV-C (colorectal/gastric) and IMV-5 (acute myeloid leukemia, on a partnering track).

Is ImmuVia a public or private company?

ImmuVia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ImmuVia founded?

ImmuVia was founded in 2017. It employs 1 to 10 people.

Where is ImmuVia based?

ImmuVia is headquartered in Cambridge, United States, in the North America region.

How does ImmuVia make money?

One revenue line is on record: pipeline development and partnering.

Who are ImmuVia's main competitors?

Emerging players on record are ProfoundBio, Compass Therapeutics and Harpoon Therapeutics. Direct peers are ImmunoGen, MacroGenics and Mersana Therapeutics. Broad incumbents are Genmab, Xencor, Elahere / AbbVie (ImmunoGen, acquired) and Zymeworks.

Does ImmuVia have an API?

No public API is recorded for ImmuVia.

What industry is ImmuVia in?

ImmuVia's product category is Bispecific Antibody Therapeutics / Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals